201 related articles for article (PubMed ID: 35280975)
1. Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study).
Goedhart TMHJ; Bukkems LH; Coppens M; Fijnvandraat KJ; Schols SEM; Schutgens REG; Eikenboom J; Heubel-Moenen FCJI; Ypma PF; Nieuwenhuizen L; Meijer K; Leebeek FWG; Mathôt RAA; Cnossen MH
TH Open; 2022 Jan; 6(1):e60-e69. PubMed ID: 35280975
[TBL] [Abstract][Full Text] [Related]
2. Predictive performance of pharmacokinetic-guided prophylactic dosing of factor concentrates in hemophilia A and B.
Goedhart TMHJ; Bukkems LH; Zwagemaker AF; Coppens M; Fijnvandraat K; Schols SEM; Schutgens REG; Eikenboom J; Heubel-Moenen FCJI; Ypma PF; Nieuwenhuizen L; Meijer K; Leebeek FWG; Mathôt RAA; Cnossen MH
Res Pract Thromb Haemost; 2024 Mar; 8(3):102397. PubMed ID: 38689619
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
Rakmanotham A; Moonla C; Sosothikul D
Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
[TBL] [Abstract][Full Text] [Related]
4. The "OPTI-CLOT" trial. A randomised controlled trial on periOperative PharmacokineTIc-guided dosing of CLOTting factor concentrate in haemophilia A.
Hazendonk HC; van Moort I; Fijnvandraat K; Kruip MJ; Laros-van Gorkom BA; van der Meer FJ; Meijer K; Peters M; Schutgens RE; Zwaan CM; Driessens MH; Polinder S; Leebeek FW; Mathôt RA; Cnossen MH
Thromb Haemost; 2015 Aug; 114(3):639-44. PubMed ID: 26062822
[TBL] [Abstract][Full Text] [Related]
5. Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis.
Srichumpuang C; Rakmanotham A; Moonla C; Sosothikul D
Orphanet J Rare Dis; 2024 Mar; 19(1):135. PubMed ID: 38532451
[TBL] [Abstract][Full Text] [Related]
6. Strategies for Individualized Dosing of Clotting Factor Concentrates and Desmopressin in Hemophilia A and B.
Preijers T; Schütte LM; Kruip MJHA; Cnossen MH; Leebeek FWG; van Hest RM; Mathôt RAA
Ther Drug Monit; 2019 Apr; 41(2):192-212. PubMed ID: 30883513
[TBL] [Abstract][Full Text] [Related]
7. Does difference between label and actual potency of factor VIII concentrate affect pharmacokinetic-guided dosing of replacement therapy in haemophilia A?
Goedhart TMHJ; Bukkems LH; van Moort I; Spence CC; Zwaan MC; de Maat MPM; Mathôt RAA; Cnossen MH;
Haemophilia; 2022 Jul; 28(4):610-618. PubMed ID: 35526235
[TBL] [Abstract][Full Text] [Related]
8. In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.
Preijers T; Bukkems L; van Spengler M; Leebeek F; Cnossen M; Mathôt R
Eur J Clin Pharmacol; 2021 Aug; 77(8):1193-1200. PubMed ID: 33624121
[TBL] [Abstract][Full Text] [Related]
9. Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: to WiN study.
Heijdra JM; Al Arashi W; de Jager NCB; Cloesmeijer ME; Bukkems LH; Zwaan CM; Leebeek FWG; Mathôt RAA; Cnossen MH;
BMJ Open; 2022 Feb; 12(2):e049493. PubMed ID: 35168962
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Pharmacokinetic-Guided Prophylaxis on Clinical Outcomes and Healthcare Resource Utilization in Hemophilia A Patients: Real-World Evidence from the CHESS II Study.
Ferri Grazzi E; Sun SX; Burke T; O'Hara J
J Blood Med; 2022; 13():505-516. PubMed ID: 36157322
[TBL] [Abstract][Full Text] [Related]
11. Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients.
Megías-Vericat JE; Bonanad S; Haya S; Cid AR; Marqués MR; Ferrada A; Monte-Boquet E; Pérez-Alenda S; Bosch P; Querol-Giner F; Poveda JL
Thromb Res; 2021 Sep; 205():99-105. PubMed ID: 34293540
[TBL] [Abstract][Full Text] [Related]
12. Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database.
Versloot O; Iserman E; Chelle P; Germini F; Edginton AN; Schutgens REG; Iorio A; Fischer K;
J Thromb Haemost; 2021 Aug; 19(8):1896-1906. PubMed ID: 34013558
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective.
Björkman S
Haemophilia; 2003 May; 9 Suppl 1():101-8; discussion 109-10. PubMed ID: 12709045
[TBL] [Abstract][Full Text] [Related]
14. Comparison Pharmacokinetic Dosing Tools in Hemophilia A Children.
Genç CA; Gürlek Gökçebay D; Koşan Çulha V; Kaya Z; Özbek NY
Indian J Hematol Blood Transfus; 2024 Jan; 40(1):108-115. PubMed ID: 38312178
[TBL] [Abstract][Full Text] [Related]
15. In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients.
Preijers T; van Spengler MWF; Meijer K; Fijnvandraat K; Fischer K; Leebeek FWG; Cnossen MH; Mathôt RAA
Eur J Clin Pharmacol; 2022 Feb; 78(2):237-249. PubMed ID: 34651201
[TBL] [Abstract][Full Text] [Related]
16. Current Understanding of Inherited Modifiers of FVIII Pharmacokinetic Variation.
Swystun LL; Lillicrap D
Pharmgenomics Pers Med; 2023; 16():239-252. PubMed ID: 36998673
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations.
Bukkems LH; Preijers T; van Spengler MWF; Leebeek FWG; Cnossen MH; Mathôt RAA
Thromb Haemost; 2021 Jun; 121(6):731-740. PubMed ID: 33506481
[TBL] [Abstract][Full Text] [Related]
18. Six-Year, Real-World Use of Prophylaxis with Recombinant Factor IX-Albumin Fusion Protein (rIX-FP) in Persons with Hemophilia B: A Single-Center Retrospective-Prospective Study.
Coppola A; Rivolta GF; Quintavalle G; Matichecchia A; Riccardi F; Rossi R; Benegiamo A; Ranalli P; Coluccio V; Tagliaferri A
J Clin Med; 2024 Mar; 13(5):. PubMed ID: 38592343
[No Abstract] [Full Text] [Related]
19. Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice.
Goedhart TMHJ; Bukkems LH; Zwaan CM; Mathôt RAA; Cnossen MH;
Blood Adv; 2021 Oct; 5(20):4314-4325. PubMed ID: 34496017
[TBL] [Abstract][Full Text] [Related]
20. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
